BRIEF published on 01/15/2026 at 11:50, 5 months 11 days ago Zürcher Kantonalbank's Disclosure on Avadel Pharmaceuticals Form 8.3 Irish Takeover Panel Securities Disclosure Zürcher Kantonalbank Avadel Pharmaceuticals
PRESS RELEASE published on 01/15/2026 at 11:45, 5 months 11 days ago Form 8.3 - Zürcher Kantonalbank: Avadel Pharmaceuticals plc Zürcher Kantonalbank discloses ownership of 0.04% of Avadel Pharmaceuticals plc shares as of 14-Jan-2026, as per Form 8.3 filing with the Irish Takeover Panel Form 8.3 Irish Takeover Panel Ownership Disclosure Zürcher Kantonalbank Avadel Pharmaceuticals Plc
BRIEF published on 01/14/2026 at 14:35, 5 months 12 days ago Zürcher Kantonalbank Discloses Position in Avadel Pharmaceuticals Ordinary Shares Disclosure Irish Takeover Panel Zürcher Kantonalbank Avadel Pharmaceuticals
PRESS RELEASE published on 01/14/2026 at 14:30, 5 months 12 days ago Form 8.3 - Zürcher Kantonalbank: Avadel Pharmaceuticals plc Zürcher Kantonalbank and subsidiaries disclosed 1.55% stake in Avadel Pharmaceuticals plc on 13th January 2026 Disclosure Irish Takeover Panel Stake Zürcher Kantonalbank Avadel Pharmaceuticals Plc
BRIEF published on 01/06/2026 at 12:50, 5 months 20 days ago Zürcher Kantonalbank Discloses Stake in Avadel Pharmaceuticals Form 8.3 Irish Takeover Panel Securities Disclosure Zürcher Kantonalbank Avadel Pharmaceuticals
PRESS RELEASE published on 01/06/2026 at 12:45, 5 months 20 days ago Form 8.3 - Zürcher Kantonalbank: Avadel Pharmaceuticals plc Zürcher Kantonalbank and subsidiaries disclose a 0.04% interest in Avadel Pharmaceuticals plc. Details of open stock-settled derivatives positions provided Disclosure Irish Takeover Panel Stock-settled Derivatives Zürcher Kantonalbank Avadel Pharmaceuticals Plc
BRIEF published on 01/05/2026 at 20:35, 5 months 21 days ago Zürcher Kantonalbank Discloses Position in Avadel Pharmaceuticals Form 8.3 Irish Takeover Panel Securities Holding Zürcher Kantonalbank Avadel Pharmaceuticals
PRESS RELEASE published on 01/05/2026 at 20:30, 5 months 21 days ago Form 8.3 - Zürcher Kantonalbank: Avadel Pharmaceuticals plc Zürcher Kantonalbank and subsidiaries disclosed a 1.02% interest in Avadel Pharmaceuticals plc shares on 2nd January 2026 Shares Disclosure Interests Zürcher Kantonalbank Avadel Pharmaceuticals Plc
BRIEF published on 01/05/2026 at 17:05, 5 months 21 days ago Zürcher Kantonalbank Discloses Position in Avadel Pharmaceuticals Form 8.3 Irish Takeover Panel Securities Disclosure Zürcher Kantonalbank Avadel Pharmaceuticals
PRESS RELEASE published on 01/05/2026 at 17:00, 5 months 21 days ago Form 8.3 - Zürcher Kantonalbank: Avadel Pharmaceuticals plc Zürcher Kantonalbank discloses 1.02% position in Avadel Pharmaceuticals plc as of 31st December 2025 following dealing activities Position Disclosure Zürcher Kantonalbank Avadel Pharmaceuticals Plc 1.02% Dealing Activities
Published on 06/27/2026 at 01:40, 9 hours 44 minutes ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 11 hours 24 minutes ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 12 hours 24 minutes ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 12 hours 34 minutes ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/26/2026 at 22:15, 13 hours 9 minutes ago Revive Therapeutics Announces Proposed Private Placement
Published on 06/27/2026 at 00:05, 11 hours 19 minutes ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 11 hours 20 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 11 hours 48 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 11 hours 48 minutes ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 11 hours 56 minutes ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
Published on 06/26/2026 at 07:00, 1 day 4 hours ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/25/2026 at 07:30, 2 days 3 hours ago Gimv signs an agreement to acquire Groupe Cap Vert, France’s leading multi-specialist provider of tree and vegetation critical management services, from Ambienta.
